Publication & Citation Trends
Publications
0 total
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. OA
Cited by 2,695
Semantic Scholar
BOLERO-2: Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive ADVANCED breast cancer refractory to letrozole or anastrozole OA
Cited by 0
Semantic Scholar
Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial.
Cited by 4
Semantic Scholar
S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial.
Cited by 41
Semantic Scholar
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer OA
Cited by 144
Semantic Scholar
Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial.
Cited by 54
Semantic Scholar
436 Trastuzumab- (H) and everolimus- (RAD001) containing regimens are safe and active when reintroduced in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) pre-treated with lapatinib
Cited by 6
Semantic Scholar
Non-Infectious Pneumonitis (NIP) in Breast Cancer (BC) Patients (Pts) Treated with Everolimus (Afinitor™) Containing Therapy: Analysis of Five Studies.
Cited by 5
Semantic Scholar
Research Topics
Acute Myocardial Infarction Research
(5)
Venous Thromboembolism Diagnosis and Management
(4)
Atrial Fibrillation Management and Outcomes
(2)
Mechanical Circulatory Support Devices
(2)
PI3K/AKT/mTOR signaling in cancer
(2)
Affiliations
Newark Beth Israel Medical Center
Novartis (Switzerland)
Novartis (France)
Pharmaleads (France)
Novartis (United States)